Nav: Home

Light scattering spectroscopy helps doctors identify early pancreatic cancer

March 13, 2017

  • New light-scattering tool offers minimally-invasive, highly accurate means of identifying pre-cancerous and cancerous pancreatic lesions.
  • Currently, no diagnostic technique exists to reliably distinguish between pre-cancerous cysts from benign ones, leading either to unnecessary surgery or untreated malignancy.

BOSTON - Pancreatic cancer has the lowest survival rate among all major cancers, largely because physicians lack diagnostic tools to detect the disease in its early, treatable stages. Now, a team of investigators led by Lev T. Perelman, PhD, Director of the Center for Advanced Biomedical Imaging and Photonics at Beth Israel Deaconess Medical Center (BIDMC), has developed a promising new tool capable of distinguishing between harmless pancreatic cysts and those with malignant potential with an overall accuracy of 95 percent. The team's preliminary data was published online today in the journal Nature Biomedical Engineering.

The new device uses light scattering spectroscopy (LSS) to detect the structural changes that occur in cancerous or pre-cancerous cells by bouncing light off tissues and analyzing the reflected spectrum. The results could help guide physicians' decision making when considering whether the presence of pancreatic cysts requires surgery, a high-risk procedure. Today, because of the lack of less-invasive diagnostic methods, more than half of these procedures turn out to have been unnecessary.

"About one-fifth of pancreatic cancers develop from cysts, but not all lesions are cancerous," said Perelman, who is also Professor of Medicine and Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School. "Considering the high risk of pancreatic surgeries and the even higher mortality from untreated pancreatic cancers, there's an obvious need for new diagnostic methods to accurately identify the pancreatic cysts that need surgical intervention and those that do not."

In Perelman and colleagues' series of experiments, the LSS technique achieved 95 percent accuracy for identifying malignancy. Cytology - the only pre-operative test currently availably - is accurate only 58 percent of the time. While the new technique requires further testing, LSS could represent a major advance against pancreatic cancer.

"This tool is a technology that is transformative in the evaluation of pancreatic cysts," said co-lead author Douglas K. Pleskow, MD, Clinical Chief of the Division of Gastroenterology and Director of the Colon and Rectal Cancer Program at the Cancer Center at BIDMC. "It provides a high level of precision in the detection of potential malignant transformation of these cysts."

Pancreatic cysts are common, and today's high-definition scanning technologies like MRI and CT imaging are detecting them with increasing frequency. Despite their high resolution, these scanners provide doctors with limited information about cysts' malignant potential.

Currently, physicians rely on minimally-invasive fine needle aspiration (FNA) biopsies to test pancreatic cysts for malignancy. The biopsy removes fluid from the cysts, which is then analyzed for cancer cells and other telltale signs of the disease, a process called cytology. However, the test fails to detect cancer about half the time, leaving high-risk surgery as the current gold-standard means of diagnosing pancreatic cysts.

To test the accuracy of the LSS system, Perelman and colleagues collected and analyzed the reflected light from 13 cysts taken from recent surgeries. Next, they compared their findings with the results from pre-operative imaging, FNA biopsies and post-operative tissues analysis. In all cases, the LSS diagnosis agreed with the post-operative analysis.

In a second experiment, the LSS tool was tested in 14 patients with pancreatic cysts who were undergoing the standard FNA biopsy. Measuring less than half a millimeter in diameter, the miniature experimental LSS fiber-optic probe was inserted in the FNA needle. Physicians spent two minutes or less measuring optical spectra from the internal cyst surface before collecting fluid from the cysts as part of the traditional biopsy. Out of nine patients whose cysts had been definitely diagnosed as either cancerous or benign, all were correctly identified by LSS.

Next, the researchers will assess the LSS system's accuracy by continuing to analyze post-operative tissues as they become available.
-end-
In addition to Perelman and Pleskow, the study authors include BIDMC investigators: co-corresponding author Le Qiu, PhD; lead author Lei Zhang, PhD; Vladimir Turzhitsky, PhD; Eric U. Yee, MD; Tyler M. Berzin, MD; Mandeep Sawhney, MD; Shweta Shinagare, MD; Edward Vitkin, PhD; Yuri Zakharov, PhD; Umar Khan; Fen Wang, MD; Jeffrey D. Goldsmith, MD; Ram Chuttani, MD; and Irving Itzkan, PhD; and Saveli Goldberg, PhD, of Massachusetts General Hospital.

This work was supported by the National Institutes of Health grants R01 EB003473 and R01 CA205431 and the National Science foundation grants CBET-1402926 and CBET-1605116. About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.

BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, MetroWest Medical Center, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit http://www.bidmc.org.

Beth Israel Deaconess Medical Center

Related Pancreatic Cancer Articles:

Bringing the 'sticky' back to pancreatic cancer
A multidisciplinary team of researchers at Japan's Tohoku University has found that a gene regulator, called BACH1, facilitates the spread of pancreatic cancer to other parts of the body.
Does lung damage speed pancreatic cancer?
High levels of CO2 in the body, due to chronic respiratory disorders, may exacerbate pancreatic cancer, making it more aggressive and resistant to therapy.
Scientists have identified the presence of cancer-suppressing cells in pancreatic cancer
Researchers have identified cells containing a protein called Meflin that has a role in restraining the progression of pancreatic cancer.
Pancreatic cancer discovery reveals how the aggressive cancer fuels its growth
A new discovery about pancreatic cancer sheds light on how the cancer fuels its growth and may help explain how promising cancer drugs work -- and for whom they will fail.
Overcoming resistance in pancreatic cancer
In pancreatic cancer cells' struggle to survive, the cells choose alternative routes when their main pathways are blocked by drugs.
Exposing how pancreatic cancer does its dirty work
Pancreatic cancer is a puzzle -- tumors slough off cells into the bloodstream early in the disease, but the tumors themselves have almost no blood vessels in them.
Targeting cell division in pancreatic cancer
Study provides new evidence of synergistic effects of drugs that inhibit cell division and support for further clinical trials.
Key to targeting the spread of pancreatic cancer
Targeting the tissue around pancreatic cancer cells may be the key to stopping their spread and improving chemotherapy outcomes.
Reprogramming pancreatic cancer
A type of white blood cell that has been especially susceptible to being deceived by pancreatic cancer cells into not attacking them can be 're-programmed' via a specially designed molecule that activates a protein found on their surfaces.
Pancreatic cancer collective comments on promising new pancreatic cancer
Lustgarten Foundation and SU2C offer comments on research describing a new combination drug therapy demonstrating promise for patients with pancreatic cancer.
More Pancreatic Cancer News and Pancreatic Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.